Surgery, Sahlgrenska Academy, University Hospital, Herlev-Gentofte, Department of Surgery, Sweden; 5 Department of Surgery, Sahlgrenska Academy, University of Gothenburg, Sweden; 5 Department of Surgery, Sahlgrenska Academy, University Hospital, Herlev-Gentofte, Denmark; 4 Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden; 5 Department of Surgery, Sahlgrenska Academy, University Hospital, Herlev-Gentofte, Denmark; 4 Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sweden; 5 Department of Surgery, Sahlgrenska Academy, University of Gothenburg, Sweden; 5 Department of Surgery, Sahlgrenska Academy, University Hospital, Herlev-Gentofte, Denmark; 4 Department of Surgery, Sahlgrenska Academy, University Hospital, Herlev-Gentofte, Denmark; 4 Department of Surgery, Sahlgrenska Academy, University of Gothenburg, Sweden; 5 Department of Surgery, Sahlgrenska Academy, University, Portland, Cregon, USA; 3 Department of Surgery, Sahlgrenska Academy, University, Portland, Cregon, USA; 3 Department of Surgery, Sahlgrenska Academy, University, Portland, Cregon, USA; 3 Department of Surgery, Sahlgrenska Academy, University, Sahlgrenska Academy, University, Sahlgrenska, Sahlgrenska Academy, University, Sahlgrenska, Sahl Seright Se Healthcare, Salt Lake City, Utah, USA; 10 Center for Dermatooncology, Eberhard Karls University of Tuebingen, Germany; 11 University of Louisville School of Medicine, Hiram C. Polk Jr, MD Department of Surgery, Louisville, KY

Introduction

- \succ In melanoma, accurate identification of T1a patients who should consider sentinel lymph node biopsy (SLNB) is important.
- > NCCN guidelines recommended consideration of SLNB for T1a melanoma patients with adverse features such as age lymphovascular invasion, and/or ≥ 2 <40 years, mitoses/ mm^2 .
- \succ This study evaluates the clinical utility of the Merlin Assay (CP-GEP model that uses clinicopathologic and gene expression variables) in stratifying T1a melanoma patients for SLNB referral, including those without adverse features.

Methods

- >This is a retrospective analysis of a cohort of 153 T1a melanoma patients from 11 centers diagnosed between 2007 and 2021 who underwent SLNB at the discretion of the treating surgeon.
- \succ CP-GEP performance was assessed by comparing the SLN positivity rate (pre-test SLN+ rate) in the entire cohort to the post-test SLN+ rates for CP-GEP Low Risk and High Risk patients.

Results


- \geq For 153 T1a melanoma patients, the overall SLN positivity rate was 3.3%.
- >CP-GEP identified 134 patients as Low Risk (88%) with a post-test SLN+ rate of 1.5%. In contrast, CP-GEP identified 19 patients as High Risk (12%) with a post-test SLN+ rate of 15.8%.
- >In T1a melanoma patients, CP-GEP achieved an SLNB reduction rate of 87.6% at a NPV of 98.5%.
- > In 49 patients with a least one adverse feature, CP-GEP identifies 37 Low Risk patients with a post-test SLN+ rate of 0% (Figure 1).
- >In 104 patients without any adverse feature, CP-GEP identifies 7 High Risk patients with a post-test SLN+ rate of 14.3% (Figure 1).

CP-GEP Identifies T1a Melanoma Patients At Risk of Sentinel Lymph Node Metastasis

W. Yu¹, A. Pazhava², M. Weitemeyer³, L. Rosenkrantz³, I. Johansson^{4,5}, R. Olofsson Bagge^{4,5}, J. Utikal^{6,7}, S. Venna⁸, J. Jackson⁹, T. Amaral¹⁰, M. Egger¹¹, A. Meves²

Patient Characteristics			Pre- and post-test p	
Variable	Level	Cohort N=153	20.0	
Gender	Female	70 (45.8%)		
	Male	83 (54.2%)	17.5	
Age (years)	Median [1QR, 3QR]	54 (41, 65)	15.0	
	<40	33 (21.6%)		
	≥40	120 (78.4%)	<u></u>	
Breslow thickness (mm)	Median [1QR-3QR]	0.6 (05, 0.7)	iii q q q 10.0	
Ulceration	Absent	153 (100.0%)	S S S S S S S S S S S S S S S S S S S	
	Present	0 (0.0%)		
	Unknown	0 (0.0%)		
SLNB outcome	Negative	148 (96.7%)	د 5.0 -	
	Positive	5 (3.3%)		
Clark level	1	0 (0.0%)		
	2	15 (9.8%)	2.5	
	3	33 (21.6%)		
	4	18 (11.8%)	0.0	
	5	0 (0.0%)	T1a - all	
	Unknown	87 (56.9%)	N SLNB pos rate	
Mitotic rate	Absent	47 (23.5%)	Pre-test 153 3.3%	
	Present	106 (69.3%)	CP-GEP Low Risk 134 1.5%	
Tumor Location	Head neck	14 (9.2%)	CP-GEP High Risk 19 15.8%	
	Trunk	38 (24.8%)	Figure 1. Pre- and post-test probabilities for	
	Upper extremities	19 (12.4%)	features such as age <40 years, lymphovascu nodal metastases. High risk post-test is the post-test is the probability of nodal metastase	
	Lower extremities	10 (6.5%)		
	Acral head	8 (5.3%)		
	Other	0 (0.0%)		
	Unknown	64 (41.8%)	Conclu	
Histologic type	Superficial spreading	61 (39.9%)	Marlin Accay may support i	
	Nodular	2 (1.3%)	Merlin Assay may support in T12 tumors	
	Lentigo maligna	9 (5.9%)	T1a tumors.	
	Acral lentiginous	2 (1.3%)	CP-GEP can support referra	
	Nevoid	2 (1.3%)	adverse features.	
	Unclassifiable	3 (2.0%)		
	Other	2 (1.3%)	CP-GEP can identify patien	
	Mixed	1 (0.7%)	metastases who otherwise	
	Unknown	71 (46.4%)	adverse features. On the	
Angiolymphatic invasion	Absent	150 (25.5%)	patients with adverse featu	
	Present	3 (2.0%)		

probabilities for SLNB positivity with CP-GEP



Ν	SLNB pos rate	Ν	SLNB pos rate
49	4.1%	104	2.9%
37	0%	97	2.1%
12	16.7%	7	14.3%

for SLNB positivity with CP-GEP in T1a cutaneous melanoma patients. Adverse cular invasion, and/or ≥2 mitoses/mm². Pre-test risk is the prevalence of having probability of nodal metastases with a High-risk CP-GEP result (red). Low-risk ases with a Low Risk CP-GEP result (blue.)

lusions & Take-home messages

in risk stratifying cutaneous melanoma patients with

al of T1a for SLNB surgery independent of traditional

ents with T1a melanoma who are at high risk of SLN would not be offered an SLNB based on lack of other hand, CP-GEP may deselect thin melanoma ures who are at low risk for nodal metastases.